Asian Phytoceuticals Public Stock Current Asset
| APCO Stock | THB 4.86 0.10 2.02% |
Asian Phytoceuticals Public fundamentals help investors to digest information that contributes to Asian Phytoceuticals' financial success or failures. It also enables traders to predict the movement of Asian Stock. The fundamental analysis module provides a way to measure Asian Phytoceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Asian Phytoceuticals stock.
Asian |
Asian Phytoceuticals Public Company Current Asset Analysis
Asian Phytoceuticals' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asian Phytoceuticals Current Asset | 433 M |
Most of Asian Phytoceuticals' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Asian Phytoceuticals Public is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Asian Phytoceuticals Public has a Current Asset of 433 M. This is 93.96% lower than that of the Personal Products sector and 87.94% lower than that of the Consumer Staples industry. The current asset for all Thailand stocks is 95.36% higher than that of the company.
Asian Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Asian Phytoceuticals' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Asian Phytoceuticals could also be used in its relative valuation, which is a method of valuing Asian Phytoceuticals by comparing valuation metrics of similar companies.Asian Phytoceuticals is currently under evaluation in current asset category among its peers.
Asian Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.08 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.35 % | |||
| Current Valuation | 2.71 B | |||
| Shares Outstanding | 600 M | |||
| Shares Owned By Insiders | 76.87 % | |||
| Price To Earning | 50.00 X | |||
| Price To Book | 5.01 X | |||
| Price To Sales | 11.94 X | |||
| Revenue | 223.35 M | |||
| Gross Profit | 177.09 M | |||
| EBITDA | 113.31 M | |||
| Net Income | 68.7 M | |||
| Cash And Equivalents | 146.48 M | |||
| Cash Per Share | 0.24 X | |||
| Total Debt | 43.19 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 4.89 X | |||
| Book Value Per Share | 0.96 X | |||
| Cash Flow From Operations | 84.4 M | |||
| Earnings Per Share | 0.12 X | |||
| Number Of Employees | 20 | |||
| Beta | 0.35 | |||
| Market Capitalization | 3.27 B | |||
| Total Asset | 680.53 M | |||
| Retained Earnings | 104 M | |||
| Working Capital | 391 M | |||
| Current Asset | 433 M | |||
| Current Liabilities | 42 M | |||
| Z Score | 45.0 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 3.34 % | |||
| Net Asset | 680.53 M | |||
| Last Dividend Paid | 0.12 |
About Asian Phytoceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Asian Phytoceuticals Public's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Asian Phytoceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Asian Phytoceuticals Public based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Asian Stock
Asian Phytoceuticals financial ratios help investors to determine whether Asian Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Asian with respect to the benefits of owning Asian Phytoceuticals security.